savolitinib + placebo

Savolitinib + placebo refers to a combination regimen used in clinical trials where one group receives the active drug savolitinib and the other receives a matching placebo. Savolitinib is an orally bioavailable small molecule inhibitor of the mesenchymal epithelial transition factor (MET) tyrosine kinase. It selectively binds to and inhibits MET receptor activity, blocking downstream signaling pathways involved in tumor cell proliferation and survival. Savolitinib is primarily developed for non-small cell lung cancer (NSCLC) with MET alterations but is also being investigated for renal cell carcinoma, gastric cancer, colorectal cancer, prostate cancer, and other solid tumors. The "placebo" component serves as an inactive comparator in randomized controlled studies[1][2][3][4].